ASN Kidney Week Early Programs 2025 – Diabetes Management for the Nephrology Care Team New Technology and New Drugs

Diabetes Management for the Nephrology Care Team: New Technology and New Drugs ASN thanks Abbott Diabetes Care Inc. and Dexcom for in-kind support (continuous glucose monitoring sensors). Course Description This program brings together members of the nephrology care team to discuss the cutting edge of rapidly advancing diabetes technologies and treatments. Diabetes is the most common cause of CKD and kidney failure requiring dialysis or kidney transplantation. Continuous glucose monitoring (CGM), insulin pumps, and closed-loop technology (automated insulin delivery [AID]) have revolutionized diabetes care. New drug classes are also available to treat diabetes and reduce CKD-related complications, including progression to kidney failure and cardiovascular disease. Nephrology care teams are well positioned to help implement new diabetes treatments according to current guidelines. Nephrology care teams often assume comprehensive care for patients with complex disease, including those with advanced CKD, kidney failure, and kidney transplants. Since many of these patients have diabetes, optimal diabetes management is an important part of their care. Given the presentation of type 1 diabetes in adults and type 2 diabetes in the pediatric population and the discovery of atypical forms of diabetes, correct diabetes classification is imperative because the treatment strategies differ depending on the etiology. Participants can engage in a voluntary CGM sensors activity to gain understanding of what it is like to wear a CGM device day after day and to be able to relate better to practitioners who treat people with diabetes. Course Objective(s) Upon completion of this program, the participant will be able to: 1) describe diabetes diagnosis, classification, and assessment; 2) discuss current technology and interpretation of CGM; 3) explain how and for whom to prescribe new diabetes drugs; and 4) describe how CGM and new treatments can be used for patients with diabetes and various stages of CKD.